C4 Therapeutics, Inc. reports developments tied to its clinical-stage targeted protein degradation business, including oncology programs designed with its TORPEDO® platform. Recurring company updates cover cemsidomide, an oral IKZF1/3 degrader being studied in relapsed/refractory multiple myeloma, as well as broader degrader-medicine research intended to address disease-causing proteins.
Company news also includes collaboration activity, such as its Roche agreement for degrader-antibody conjugates, along with clinical disclosures, operating and financial results, conference participation, equity inducement grants, and other governance matters under Nasdaq rules.
On October 14-15, 2020, C4 Therapeutics (Nasdaq: CCCC) will present at the 3rd Annual Targeted Protein Degradation Summit. Dr. Rhamy Zeid will discuss the use of C4T’s TORPEDO™ platform for developing selective protein degraders, focusing on CFT8634 for synovial sarcoma. Dr. Stewart Fisher will lead a roundtable on the challenges and opportunities in drug discovery. The company aims to optimize protein degradation to provide new treatments for cancer and neurodegenerative diseases, showcasing its innovative approach in the biopharmaceutical industry.
C4 Therapeutics, a biopharmaceutical company focused on developing small-molecule drugs to degrade disease-causing proteins, announced the successful closing of its initial public offering (IPO) on October 6, 2020. The company sold 11.04 million shares, including 1.44 million additional shares purchased through underwriters' options, priced at $19.00 each. This resulted in gross proceeds of approximately $209.76 million, before expenses. The IPO is managed by Jefferies, Evercore ISI, BMO Capital Markets, and UBS Investment Bank.
C4 Therapeutics (Nasdaq: CCCC) has priced its upsized initial public offering at $19 per share, offering 9.6 million shares for gross proceeds of approximately $182.4 million. The offering is scheduled to begin trading on the Nasdaq Global Market on October 2, 2020, and is expected to close on October 6, 2020, pending customary closing conditions. The company has also granted underwriters a 30-day option to purchase an additional 1.44 million shares. C4T focuses on developing small-molecule drugs to selectively degrade disease-causing proteins for cancer and neurodegenerative conditions.